Biocon Biologics Limited, a fully integrated global biosimilars company and a subsidiary of Biocon Limited, has been recognised as an Asia IP Elite organization for the year 2025 by Intellectual Asset Management (IAM), a globally respected publication focused on intellectual property strategy. The recognition was announced during the Intellectual Property Business Congress Asia held in Tokyo from November 18 to 20, 2025. The Asia IP Elite distinction is awarded to a select group of organisations across the region that demonstrate strong capabilities in managing intellectual property and consistently creating long-term value through innovation and strategic IP practices.
Biocon first received this recognition in 2016, becoming the only Indian pharmaceutical company at that time to be featured on the Asia IP Elite list. Since then, both Biocon and Biocon Biologics have maintained their position among the region’s leading IP-driven organisations. The 2025 recognition marks the ninth consecutive year that the group has been included, reflecting a sustained commitment to innovation, research excellence, and effective intellectual property governance.
Commenting on the achievement, Shreehas Tambe, Chief Executive Officer and Managing Director of Biocon Biologics, stated that the continued inclusion highlights the company’s long-term focus on innovation and a disciplined approach to intellectual property management. He added that a strong IP foundation has been critical in supporting Biocon Biologics’ growth as a global biosimilars leader and in enabling the company to expand access to affordable, high-quality therapies for patients across the world.
IAM’s selection process involves extensive qualitative and quantitative research to identify organisations that lead in IP value creation and strategic deployment. The Asia IP Elite list recognises companies that view intellectual property not only as a legal safeguard but as a core business asset that drives competitiveness and growth.
Biocon Biologics serves more than 6.3 million patients across over 120 countries through its end-to-end capabilities, spanning research, development, manufacturing, and commercialization. The company has successfully launched 10 biosimilars in key regulated and emerging markets, including the United States, Europe, Japan, Canada, and Australia, and continues to advance a robust pipeline of biosimilar assets across multiple therapeutic areas. Through innovation, scale, and a strong commitment to sustainability, Biocon Biologics continues to strengthen its role in transforming healthcare outcomes globally.
